MeSH D002544 - cerebral infarction
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D020520:Brain infarction
0 Companies
0 Drugs
Success rate
D002544:Â
Cerebral infarction
D015161:Multi-infarct dementia
0 Companies
0 Drugs
Success rate
D020243:Anterior cerebral artery infarction
0 Companies
0 Drugs
Success rate
D020244:Middle cerebral artery infarction
0 Companies
0 Drugs
Success rate
D020762:Posterior cerebral artery infarction
0 Companies
0 Drugs
Success rate
D046589:Cadasil
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Heparin sodium | Heparin |  | 2017-11-30 |  |  |
| Sandoz | Heparin sodium | Heparin |  | 2011-06-08 |  |  |
| Aspen Global | Heparin | Liquaemin |  | 1982-01-01 |  |  |
| Novartis | Heparin, Lidocaine, Dihydroergotamine | Embolex |  | 1984-11-30 |  |  |
| Sanofi | Heparin | Calciparine |  | 1982-01-01 |  |  |
| 3M | Heparin | Lipo-hepin |  | 1982-01-01 |  |  |
| Pfizer | Heparin | Heparin |  | 1982-01-01 |  |  |
| Eli Lilly | Heparin | Heparin |  | 1982-01-01 |  |  |
| Dr Reddys Laboratories | Heparin | Heparin |  | 1996-06-07 |  |  |
| Hospira | Heparin | Heparin |  | 1996-07-26 |  |  |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
100%3/3
Phase 2
40%4/10
Phase 3
40%6/15
Approved: 2Overall Success rate: 16%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use